Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:1

Sadržaj

članak: 1 od 4  
Back povratak na rezultate
2020, vol. 148, br. 11-12, str. 742-748
Prevod i psihometrijske performanse srpske verzije upitnika "Kvalitet života sa sarkopenijom" (Sarqol®)
aKlinički centar Vojvodine, Novi Sad
bUniverzitet u Novom Sadu, Fakultet tehničkih nauka
cUniverzitet u Kopenhagenu, Fakultet prirodnih nauka, Katedra za računarstvo i informatiku, Kopenhagen, Danska
dUniverzitet u Liježu, Odeljenje za javno zdravstvo, epidemiologiju i zdravstvenu ekonomiju, Centar za saradnju Svetske zdravstvene organizacije za javno zdravlje sa aspektima muskulo-skeletnog zdravlja i starenja, Lijež, Belgija
eUniverzitet Privredna akademija u Novom Sadu

e-adresaanton.geerinck@uliege.be
Ključne reči: sarkopenija; kvalitet života; SarQoL, validacija
Sažetak
Uvod/Cilj Upitnik "Kvalitet života sa sarkopenijom" (SarQoL®) koji popunjavaju bolesnici specifičan je za sarkopeniju. Cilj je bio da se prevede upitnik sa engleskog na srpski jezik i ispitaju njegove psihometrijske performanse. Metode Upitnik je preveden. Ispitanici su bili penzioneri oba pola, stariji od 65 godina. Tri metode su korišćene za utvrđivanje sarkopenije: upitnik SARC-F, smanjena snaga stiska i kompletni kriterijumi Evropske radne grupe za sarkopeniju kod starijih osoba (EWGSOP2). Ispitivani su diskriminativna sposobnost, interna konzistencija, konstrukciona validnost, efekat poda i plafona. Rezultati Upitnik SarQoL® je preveden na srpski jezik. Validaciona studija je sprovedena na 699 ispitanika. Od ukupnog broja, 200 učesnika pripadaju visokorizičnoj grupi za sarkopeniju na osnovu upitnika SARC-F, 84 ispitanika je imalo oslabljenu snagu stiska šake, a 12 potvrđenu sarkopeniju. Na osnovu kriterijuma EWGSOP2 nije ustanovljen značajno manji kvalitet života (60,31 vs. 64,60; p = 0,155). Dobijene su niže vrednosti upitnika SarQoL® za grupu sa manjim rizikom za sarkopeniju (52,80 vs. 65,50; p < 0,001) i visokorizičnu grupu za sarkopeniju (50,91 vs. 69,02; p < 0,001). Kronbahov alfa koeficijent je iznosio 0,87, što ukazuje na visoku internu konzistenciju. Konstruktivna validnost je bila adekvatna i potvrđena sa 75% i očekivanom korelacijom sa upitnicima SF-36 i EQ-5D. Nije uočen efekat poda/plafona u dobijenim rezultatima. Zaključak Upitnik SarQoL® je uspešno preveden na srpski jezik i potvrđena je njegova validnost za utvrđivanje kvaliteta života gerijatrijske populacije.
Reference
Naknadno pridodat članak: provera, normiranje i linkovanje referenci u toku.
Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 2010;39(4):412-23
Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31
Beaudart C, McCloskey E, Bruyère O, Cesari M, Rolland Y, Rizzoli R, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16(1):170
Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world: a systematic review and meta-analysis of general population studies. J Diabetes Metab Disord. 2017;16:16:21
United Nations. World Population Ageing. Population Division, Department of Economic and Social Affairs; 2019
Ethgen O, Beaudart C, Buckinx F, Bruyère O, Reginster JY. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017;100(3):229-34
Jakovljevic M. Population ageing alongside health care spending growth. Srpski arhiv za celokupno lekarstvo. 2017;145(9-10):113-29
Geerinck A, Bruyère O, Locquet M, Reginster J, Beaudart C. Evaluation of the Responsiveness of the SarQoL® Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia. Adv Ther. 2018;35(11):1842-58
Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing. 2015;44(6):960-6
The SarQoL questionnaire [Internet]. [Online]. [cited 2020 February 16]. Available from: http://www.sarqol.org
Beaudart C, Biver E, Reginster J, Rizzoli R, Rolland Y, Bautmans I, et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8(2):238-44
Beaudart C, Edwards M, Moss C, Reginster J, Moon R, Parsons C, et al. English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age Ageing. 2017;46(2):271-6
Gasparik A, Mihai G, Beaudart C, Bruyere O, Pop R, Reginster J, et al. Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Arch Osteoporos. 2018;13(1):98
Hodinka L, Vereckei E, Gasparik A. Sarcopenia and quality of life: the validated Hungarian translation of the Sarcopenia Quality of Life (SarQoL) questionnaire. Orv Hetil. 159(36):1483-6
Konstantynowicz J, Abramowicz P, Glinkowski W, Taranta E, Marcinowicz L, Dymitrowicz M, et al. Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. J Clin Med. 2018;7(10):323
Tsekoura M, Billis E, Gliatis J, Tsepis E, Matzaroglou C, Sakkas G, et al. Cross cultural adaptation of the Greek sarcopenia quality of life (SarQoL) questionnaire. Disabil Rehabil. 2020;42(7):1006-12
Geerinck A, Scheppers A, Beaudart C, Bruyère O, Vandenbussche W, Bautmans R, et al. Translation and validation of the Dutch SarQoL®, a quality of life questionnaire specific to sarcopenia. J Musculoskelet Neuronal Interact. 2018;18(4):463-72
Fábrega-Cuadros R, Martínez-Amat A, Cruz-Díaz D, Aibar-Almazán A, Hita-Contreras F. Psychometric Properties of the Spanish Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia. Calcif Tissue Int. 2020;106(3):274-82
Alekna V, Kilaite J, Tamulaitiene M, Geerinck A, Mastaviciute A, Bruyère O, et al. Validation of the Lithuanian version of sarcopeniaspecific quality of life questionnaire (SarQoL®). Eur Geriatr Med. 2019;10:761-7
Safonova Y, Lesnyak O, Baranova I, Suleimanova A, Zotkin E. Russian translation and validation of SarQoL® -quality of life questionnaire for patients with sarcopenia. Rheumatology Science and Practice. 2019;57(1):38-45
Beaton D, Bombardier C, Guillemin F, Ferraz M. Guidelines for the process of crosscultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25(24):3186-91
Malmstrom T, Morley J. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013;14(8):531-2
Roberts H, Denison H, Martin H, Patel H, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423-9
Terwee C, Bot S, de Boer M, van der Windt D, Knol D, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34-42
Karran J, Moodie E, Wallace M. Statistical method use in public health research. Scand J Public Health. 2015;43(7):776-82
Cruz-Jentoft A, Landi F, Schneider S, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014;43(6):748-59
Lu JL, Ding LY, Xu Q. Screening Accuracy of SARC-F for Sarcopenia in the Elderly: A Diagnostic Meta-Analysis. J Nutr Health Aging (2020)
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH200924114M
primljen: 24.09.2020.
revidiran: 08.12.2020.
prihvaćen: 09.12.2020.
objavljen onlajn: 10.12.2020.
objavljen u SCIndeksu: 06.01.2021.

Povezani članci

Nema povezanih članaka